# US 9,040,298 B2 · Method of selecting stem cells having high chondrogenic differentiation capability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,298 B2
- Document ID: US9040298B2
- Status: Granted
- Kind: B2
- Application number: 12/790,268
- Filed: 2010-05-28
- Published: 2010-12-02
- Granted: 2015-05-26
- Earliest claimed: 2009-05-29
- Assignees: Medipost Co., Ltd.
- Applicants: Yoon-Sun Yang; Won Il Oh; Hong Bae Jeon; Mee Hyun Jung; Sang Young Jeong
- Inventors: Yoon-Sun Yang; Won Il Oh; Hong Bae Jeon; Mee Hyun Jung; Sang Young Jeong
- Web page: https://patentgrep.com/patent/US9040298B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.

## Claims

### Claim 1

A method of selecting a stem cell capable of differentiating into a chondrocyte or inducing chondrocyte differentiation, the method comprising:
culturing a stem cell in a monolayer or pellet in a maintenance medium;
measuring a concentration of TSP-2; and
selecting and isolating a stem cell having a high chondrogenic differentiation capability from the culture medium if
a) the concentration of TSP-2 in cell culture is larger than 72 pg/ml/1.0×105 cells when the stem cell is monolayer cultured for 1 day, or
b) the concentration of TSP-2 in cell culture is larger than 550 pg/ml/1.0×105 cells when the stem cell is pellet cultured for 7 days,
wherein the selected stem cell is capable of differentiating into a chondrocyte or inducing chondrocyte differentiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem cell is an umbilical cord blood mesenchymal stem cell (UCB-MSC).

### Claim 3 (depends on 1)

The method of claim 1, wherein the stem cell may be selected from the group consisting of an induced pluripotent stem cell (iPS cell), an embryonic stem cell, and an adult stem cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stem cell may be selected from the group consisting of a mesenchymal stem cell (MSC), an adipose-derived stem cell, an endothelial stem cell, and a hematopoietic stem cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein said method further comprises differentiating said stem cells in vitro or in vivo.